- Home
- MFA vs AVDL Comparison
MFA vs AVDL Comparison
Compare MFA & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- AVDL
- Stock Information
- Founded
- MFA 1997
- AVDL 2015
- Country
- MFA United States
- AVDL Ireland
- Employees
- MFA N/A
- AVDL N/A
- Industry
- MFA Real Estate Investment Trusts
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- AVDL Health Care
- Exchange
- MFA Nasdaq
- AVDL Nasdaq
- Market Cap
- MFA 1.1B
- AVDL 786.3M
- IPO Year
- MFA N/A
- AVDL 1996
- Fundamental
- Price
- MFA $10.11
- AVDL $7.75
- Analyst Decision
- MFA Buy
- AVDL Strong Buy
- Analyst Count
- MFA 4
- AVDL 6
- Target Price
- MFA $13.75
- AVDL $20.00
- AVG Volume (30 Days)
- MFA 1.3M
- AVDL 1.5M
- Earning Date
- MFA 02-20-2025
- AVDL 03-03-2025
- Dividend Yield
- MFA 13.86%
- AVDL N/A
- EPS Growth
- MFA N/A
- AVDL N/A
- EPS
- MFA 1.60
- AVDL N/A
- Revenue
- MFA $366,192,000.00
- AVDL $138,160,000.00
- Revenue This Year
- MFA N/A
- AVDL $523.86
- Revenue Next Year
- MFA $14.93
- AVDL $70.46
- P/E Ratio
- MFA $6.31
- AVDL N/A
- Revenue Growth
- MFA 164.50
- AVDL 1523.50
- 52 Week Low
- MFA $9.36
- AVDL $7.39
- 52 Week High
- MFA $13.45
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- MFA 43.29
- AVDL 27.63
- Support Level
- MFA $9.36
- AVDL $7.39
- Resistance Level
- MFA $10.40
- AVDL $8.74
- Average True Range (ATR)
- MFA 0.22
- AVDL 0.48
- MACD
- MFA 0.03
- AVDL -0.24
- Stochastic Oscillator
- MFA 61.57
- AVDL 8.72
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.